Science and Technology News and Videos
, drugmaker Eli Lilly declared that it "stands against the use of its medicines for cosmetic weight loss" — even as people using the Ozempic competitors for that very purpose have made the companyThe Indianapolis-based company added that because tirzepatide has not been tested on people who have gastrointestinal disorders such as pancreatitis and gastroparesis, people who have those conditions should avoid the drug.
Though it didn't mention it by name, the specter of Denmark's Novo Nordisk, which makes the diabetes injection Ozempic and its weight loss sister drug Wegovy, hangs heavy over Lilly letter. The pharma firm cautioned that tirzepatide should not be taken by anyone under 18 and will never be advertised on social media — two issues that have become salient for Nordisk as
The rival firms' interests dovetail towards the end of the open letter, where Lilly issued a stark warning about buying and using compounded tirzepatide from"Be aware that when you purchase products that are not FDA-approved medicines or obtain medicines from an unverified source or without a prescription from a licensed healthcare provider, you may be purchasing fake, counterfeit, or otherwise unsafe products," the letter cautioned.
It's an intriguing positioning for the pharma giant. Entire fields of treatment — think botox, or lip filler, or Brazilian butt lifts — have essentially no purposeto address patients' cosmetic concerns about their bodies. Will drugs like semaglutide and tirzepatide chart a different course, with their makers positioning them as strictly medical? For now, that certainly feels like Lilly's strategy.
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Eli Lilly to invest another $5.3 billion in Indiana plant to expand Mounjaro, Zepbound supplyDemand for the drugs Mounjaro and Zepbound has far outpaced supply over the last year, forcing Eli Lilly to invest heavily to scale up its manufacturing.
Read more »
Eli Lilly beefs up plan to expand manufacturing for popular drugs Zepbound, MounjaroEli Lilly will spend more than $5 billion to expand an Indiana manufacturing site and eventually make more doses of its hot-selling weight-loss and diabetes treatments, Zepbound and Mounjaro. The drugmaker said Friday that it was more than doubling its investment in a site near its Indianapolis headquarters.
Read more »
Eli Lilly beefs up plan to expand manufacturing for popular drugs Zepbound, MounjaroEli Lilly will spend more than $5 billion to expand an Indiana manufacturing site and eventually make more doses of its hot-selling weight-loss and diabetes treatments, Zepbound and Mounjaro.
Read more »
Eli Lilly beefs up plan to expand manufacturing for popular drugs Zepbound, MounjaroEli Lilly will spend more than $5 billion to expand an Indiana manufacturing site and eventually make more doses of its hot-selling weight-loss and diabetes treatments, Zepbound and Mounjaro.
Read more »
Eli Lilly's big GLP-1 investment — plus, what we want from 4 portfolio stock earningsThe Investing Club holds its 'Morning Meeting' every weekday at 10:20 a.m. ET.
Read more »
Mounjaro And Zepbound Shortages Targeted With $5.3 Billion Eli Lilly InvestmentI cover breaking news for Forbes. Before Forbes, I worked as a reporter for USA Today in Asheville and Black Mountain, North Carolina. I received my bachelor's degree in journalism from Auburn University and my master's degree in journalism from Northwestern University.
Read more »